- Home
- CLMT vs ARVN Comparison
CLMT vs ARVN Comparison
Compare CLMT & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLMT
- ARVN
- Stock Information
- Founded
- CLMT 1916
- ARVN 2015
- Country
- CLMT United States
- ARVN United States
- Employees
- CLMT N/A
- ARVN N/A
- Industry
- CLMT Oil & Gas Production
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- CLMT Energy
- ARVN Health Care
- Exchange
- CLMT Nasdaq
- ARVN Nasdaq
- Market Cap
- CLMT 1.4B
- ARVN 1.2B
- IPO Year
- CLMT 2006
- ARVN 2018
- Fundamental
- Price
- CLMT $13.16
- ARVN $7.59
- Analyst Decision
- CLMT Strong Buy
- ARVN Buy
- Analyst Count
- CLMT 5
- ARVN 13
- Target Price
- CLMT $22.80
- ARVN $34.42
- AVG Volume (30 Days)
- CLMT 1.4M
- ARVN 3.4M
- Earning Date
- CLMT 05-09-2025
- ARVN 05-06-2025
- Dividend Yield
- CLMT N/A
- ARVN N/A
- EPS Growth
- CLMT N/A
- ARVN N/A
- EPS
- CLMT N/A
- ARVN N/A
- Revenue
- CLMT $4,189,399,999.00
- ARVN $263,399,999.00
- Revenue This Year
- CLMT N/A
- ARVN N/A
- Revenue Next Year
- CLMT N/A
- ARVN $7.99
- P/E Ratio
- CLMT N/A
- ARVN N/A
- Revenue Growth
- CLMT 0.20
- ARVN 235.54
- 52 Week Low
- CLMT $9.97
- ARVN $7.53
- 52 Week High
- CLMT $25.29
- ARVN $41.34
- Technical
- Relative Strength Index (RSI)
- CLMT 47.70
- ARVN 25.11
- Support Level
- CLMT $11.91
- ARVN $8.51
- Resistance Level
- CLMT $13.51
- ARVN $9.17
- Average True Range (ATR)
- CLMT 0.77
- ARVN 0.72
- MACD
- CLMT 0.27
- ARVN -0.07
- Stochastic Oscillator
- CLMT 88.41
- ARVN 1.85
About CLMT Calumet Specialty Products Partners L.P. Common Units
Calumet Inc is a producer of specialty products, including base oils, specialty oils, solvents, esters, and waxes, as well as a variety of fuel and fuel-related products, including asphalt and heavy fuel oils. The company manufactures, formulates, and markets a variety of specialty branded products to customers in various consumer-facing and industrial markets.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.